Foghorn Therapeutics Inc. - Common Stock (NQ:FHTX)

2.600 -0.970 (-27.17%)

Delayed Quote Updated: 11:58 AM EDT, Oct 1, 2026 Add to My Watchlist

Price and Volume

Volume	8,946,470
Open	2.080
Bid (Size)	2.580 (2,300)
Ask (Size)	2.600 (100)
Prev. Close	3.570
Today's Range	1.790 - 2.610
52wk Range	3.270 - 7.610
Shares Outstanding	36,936,886
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Thursday's session: gap up and gap down stocks ↗

Today 10:30 EDT

Via Chartmill

These stocks that are showing activity before the opening bell on Thursday. ↗

Today 8:30 EDT

Via Chartmill

Performance

YTD	-49.9%	-49.9%
1 Month	-54.7%	-54.7%
3 Month	-48.1%	-48.1%
6 Month	-46.9%	-46.9%
1 Year	-46.8%	-46.8%

More News

Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities

Today 7:00 EDT

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update

August 06, 2026

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Targets Next Wave of DNA Damage Response Cancer Therapies

June 22, 2026

Via Investor Brand Network

Next-Generation DNA Repair Therapies Open New Frontiers in Oncology

June 22, 2026

Via Investor Brand Network

Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

June 05, 2026

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May

May 12, 2026

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update

May 07, 2026

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

April 21, 2026

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

April 09, 2026

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

March 11, 2026

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

February 24, 2026

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer

February 23, 2026

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit

February 03, 2026

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium

January 13, 2026

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

January 09, 2026

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

November 25, 2025

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

This Aardvark Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday ↗

November 07, 2025

Via Benzinga

Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update

November 05, 2025

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

These stocks are gapping in today's session ↗

November 04, 2025

Via Chartmill

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

November 03, 2025

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs

October 30, 2025

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit

October 16, 2025

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

August 27, 2025

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Foghorn Therapeutics Inc. - Common Stock publicly traded?

Yes, Foghorn Therapeutics Inc. - Common Stock is publicly traded.

What exchange does Foghorn Therapeutics Inc. - Common Stock trade on?

Foghorn Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Foghorn Therapeutics Inc. - Common Stock?

The ticker symbol for Foghorn Therapeutics Inc. - Common Stock is FHTX on the Nasdaq Stock Market

What is the current price of Foghorn Therapeutics Inc. - Common Stock?

The current price of Foghorn Therapeutics Inc. - Common Stock is 2.600

When was Foghorn Therapeutics Inc. - Common Stock last traded?

The last trade of Foghorn Therapeutics Inc. - Common Stock was at 10/01/26 11:58 AM ET

What is the market capitalization of Foghorn Therapeutics Inc. - Common Stock?

The market capitalization of Foghorn Therapeutics Inc. - Common Stock is 96.03M

How many shares of Foghorn Therapeutics Inc. - Common Stock are outstanding?

Foghorn Therapeutics Inc. - Common Stock has 96M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.